These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1272548)

  • 21. Compliance with hormonal treatment for prostate cancer.
    Kaisary AV
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):359-66. PubMed ID: 8696636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cosmetic orchiectomy for prostate cancer.
    Chiou RK
    Urol Clin North Am; 1990 Feb; 17(1):13-6. PubMed ID: 2305508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 24. Total androgen ablation: Canadian experience.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. re: Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. R. Haapiainen et al. Br. J. Urol., 66, 94-97, 1990.
    Bishop MC
    Br J Urol; 1991 Aug; 68(2):218. PubMed ID: 1884161
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more.
    Dieli F; Caccamo N; Meraviglia S
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1089-94. PubMed ID: 18821471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Orchiectomy and buserelin in combination with flutamide: comparative results in metastatic prostatic carcinoma].
    Mora MJ; Extramiana J; Paniagua P; González P; Mañas A; Pérez MJ; Navarro J; Arrizabalaga M
    Actas Urol Esp; 1991; 15(6):548-52. PubMed ID: 1792994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
    Kaisary AV
    Prostate Cancer Prostatic Dis; 2005; 8(2):140-51. PubMed ID: 15852051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Radiotherapy and early orchiectomy in stage D1 prostatic carcinoma].
    Wiegel T
    Strahlenther Onkol; 1995 Jul; 171(7):419-20. PubMed ID: 7631267
    [No Abstract]   [Full Text] [Related]  

  • 31. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment.
    Lindström P; Bergh A; Holm I; Damber JE
    Prostate; 1996 Oct; 29(4):209-18. PubMed ID: 8876704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
    Nickerson T; Miyake H; Gleave ME; Pollak M
    Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Osteoporosis after orchiectomy for prostate cancer.
    Pavlovich CP; Pitts WR
    J Urol; 1999 Oct; 162(4):1392. PubMed ID: 10492219
    [No Abstract]   [Full Text] [Related]  

  • 35. Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
    Veshapidze N; Chigogidze T; Managadze L; Gabunia N; Kotrikadze N
    Georgian Med News; 2007 Dec; (153):11-4. PubMed ID: 18250488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Castration as a better alternative to estrogen in the treatment of prostatic cancer].
    Edhag O; Henriksson P; Linde B; Eriksson A; Collste L
    Lakartidningen; 1987 Oct; 84(42):3394-6. PubMed ID: 3683028
    [No Abstract]   [Full Text] [Related]  

  • 38. The fate of the medically castrated testis: expectation versus reality.
    Issa MM; Krishnan A; Bouet R; Young MR; Hood N; Petros JA
    J Urol; 2004 Sep; 172(3):1042-4. PubMed ID: 15311033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the increase in orchiectomy for prostate cancer patients appropriate?
    Chodak GW
    Cancer; 2008 May; 112(10):2106-7. PubMed ID: 18386828
    [No Abstract]   [Full Text] [Related]  

  • 40. Osteoporosis after orchiectomy for prostate cancer.
    Daniell HW
    J Urol; 1997 Feb; 157(2):439-44. PubMed ID: 8996327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.